David Hough, M.D., is a board-certified psychiatrist and pharmaceutical executive with deep expertise in central nervous system (CNS) drug development. He previously served as Vice President of Research and Development at J&J Innovative Medicine (a Johnson & Johnson company) and other leadership roles over the course of 17 years. He was the compound development team leader for INVEGA (paliperidone), INVEGA SUSTENNA, and INVEGA TRINZA as well as for SPRAVATO®️ (esketamine nasal spray), where he was responsible for all medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program. Prior to his work at J&J, Dr. Hough graduated from West Point and served as an Army officer before attending medical school at the Uniformed Services University of the Health Sciences (USUHS). He completed his residency training in Psychiatry at Walter Reed Medical Center and subsequently served for 10 years as an Army psychiatrist, where he treated soldiers, retirees, and family members with a variety of behavioral health issues, including many with trauma and PTSD. He is board certified in both Adult and Geriatric Psychiatry, and he previously held an Adjunct Assistant Professor of Psychiatry position at USUHS. He has authored numerous publications in peer reviewed journals, is a reviewer for several journals, and was an examiner for the American Board of Psychiatry and Neurology.
Executive Committee